#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Spiro Rombotis Email
President & CEO . Cyclacel Pharmaceuticals
How to contact Spiro Rombotis
Join and see Spiro's contact info for free!Current Roles
Employees:
15Revenue:
$3.5MAbout
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Cyclacel's discovery engines integrate cell cycle biology expertise with a large library of gene-based targets, RNAi functional genomics, chemogenomics and clinical biomarker technologies to deliver new drugs. The company is currently evaluating seliciclib (CYC202), an orally-available Cyclin Dependent Kinase inhibitor, in Phase II clinical trials for the treatment of non-small cell lung cancer and B-cell hematological malignancies. CYC682 is an orally-available, cell cycle modulating nucleoside analog in Phase I clinical trials for the treatment of cancer. Cyclacel has eight additional programs at preclinical stages. Cyclacel has entered into corporate alliances with Altana, AstraZeneca, CV Therapeutics, GlaxoSmithKline, Lorus and Sankyo all in the oncology field. Cyclacel is the first European university spin-out company to have raised more than $100 million in private equity.Cyclacel Pharmaceuticals Address
200 Connell DriveBerkeley Heights, NJ
United States